Company / FCF Margin
Travere Therapeutics, Inc. FCF Margin History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-193.3%
FY2023
5-year range
-193.3% / -33.3%
FY2019-FY2023
Trend
-13.4%
vs FY2022
Sector context
#98 of 134
Health Care
What the data says
At -193.3%, Travere Therapeutics, Inc.'s fcf margin ranks #98 of 134 in the Health Care sector. FCF Margin has declined for 4 consecutive years, from 4.2% in FY2019 to -193.3% in FY2023.
Based on SEC 10-K filings.
-193.3% in FY2023 with a 5-year CAGR of -189.6%.
Declined from -33.3% to -193.3% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -177.6pp
- 5-Year Change
- -189.6pp
- 10-Year Change
- -
Sector benchmark
#98 of 134 in Health CareTop 73% of 134This company -193.3% Sector average -637.8%
▼
+69.7% above sector average
Key checks
Key Insights
- Travere Therapeutics, Inc.'s fcf margin has declined for 4 consecutive years.
- In FY2023, fcf margin decreased 13.4% year-over-year.
- Currently 444.5pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -193.3% | -13.4% |
| FY2022 | -170.4% | -411.5% |
| FY2021 | -33.3% | -113.0% |
| FY2020 | -15.6% | -471.5% |
| FY2019 | 4.2% | +215.7% |
| FY2018 | -3.6% | -158.2% |
| FY2017 | -1.4% | +99.1% |
| FY2016 | -164.9% | -11596.5% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026